Literature DB >> 28874622

Predictors of central lymph node metastasis in papillary thyroid cancer.

Huseyin Celik, Ozgur Akgul, Barıs Dogu Yıldız, Barıs Saylam, Mesut Tez.   

Abstract

INTRODUCTION: Papillary thyroid carcinoma (PTC) is the most common malignancy of the thyroid gland and although PTC has excellent prognosis, central lymph node (CLN) metastases are not uncommon. Studies have shown that CLN metastases are associated with an increased recurrence rate. The necessity for prophylactic CLN dissection (pCCND) in clinical lymph node negative (cN0) patients remains controversial. The aim of this study was to determine predictors of CLN metastases in cN0 PTC patients who underwent prophylactic CLN dissection.
MATERIALS AND METHODS: The medical charts of 97 patients with cN0 PTC who had undergone total thyroidectomy (TT) and pCCND were evaluated retrospectively. The relationship between CLN metastases and risk factors were analyzed.
RESULTS: CLN metastases were found in 32 (32.9%) patients. Univariate analysis showed that CLN metastases were significantly associated with male sex and tumor size. In multivariate analysis, tumor size greater than 0.7 cm and male sex were independent predictors for CLN metastases. DISCUSSION: Although oncological benefits of the pCCND in cN0 PTC patients remain controversial, tumor size greater than 0.7cm and male gender may be possible indicators of central lymph node metastasis. KEY WORDS: Central lymph node metastasis, Central lymph node dissection, Papillary Thyroid Cancer, Total thyroidectomy.

Entities:  

Mesh:

Year:  2017        PMID: 28874622

Source DB:  PubMed          Journal:  Ann Ital Chir        ISSN: 0003-469X            Impact factor:   0.766


  1 in total

1.  Meis homeobox 2 (MEIS2) inhibits the proliferation and promotes apoptosis of thyroid cancer cell and through the NF-κB signaling pathway.

Authors:  Xiaohui Wen; Mingyu Liu; Jingyan Du; Xun Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.